Replexa+NCT07336381
Shortwave Diathermy In-home Treatment for Indianapolis VA-only Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Withdrawn before enrolling Sponsor's reason: Funding issues Show 5 more changesShow less
- Enrollment target: estimated 10 to confirmed 0
- Eligibility criteria expanded, about 19 words
- Primary completion date changed from estimate of Dec 31, 2027 to Sep 24, 2026
- Start date changed from estimate of Jul 1, 2026 to Sep 24, 2026
- Site contact updated
Notable Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027v3 Show 4 more changesShow less
- Start date: Dec 5, 2025 to Jul 1, 2026
- Trial status changed: Recruiting → Not Yet Recruiting
- Site details revised
- Study title expanded, about 2 words
- Notable Primary endpoint revisedv2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Compare baseline and post-treatment lower extremity arterial dopplers to determine change in lower extremity arterial perfusion.
Timeframe: 3 months
Secondary (1)
Identify the presence and role of inflammatory biomarkers in PAD.
Arms and interventions
InterventionExperimental
In-home shortwave diathermy treatment.
Devices: Replexa shortwave diathermy
Sites
1 site in 1 country
- Richard L. Roudebush Veterans Affairs Medical CenterIndianapolis, Indiana, United States